Login to Your Account



EMA goes PRO, seeks more patient input in regulatory process

By Nuala Moran
Staff Writer

Friday, June 20, 2014
LONDON – The EMA has launched a consultation on factoring patient-related outcomes into the regulatory process for oncology drugs, as a next step in its efforts to turn patient sentiment into hard data and speed up its approval processes.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription